Te‐Chun Hsia
Impact in
- Oncology top 1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 31
- Lung Cancer Diagnosis and Treatment 10
-
- Protease and Inhibitor Mechanisms 12
- Co-authors
- Jing‐Gung Chung (16 shared papers)Chih‐Yen Tu (37 shared papers)Te‐Chun Shen (34 shared papers)DA-TIAN BAU (40 shared papers)Jai‐Sing Yang (6 shared papers)Chia‐Hung Chen (22 shared papers)WEN-SHIN CHANG (41 shared papers)Wu‐Huei Hsu (18 shared papers)
- Journals
- Anticancer Research (17 papers)Medicine (7 papers)Environmental Toxicology (4 papers)Journal of Thoracic Oncology (4 papers)The Lancet Oncology (3 papers)
- Partner nations
- TaiwanChinaUnited States
In The Last Decade
Te‐Chun Hsia
148 papers receiving 5.8k citations
Te‐Chun Hsia's Hit Papers
Peers
Comparison fields: 5 of 112
- Oncology 2.6k
- Pulmonary and Respiratory Medicine 1.7k
- Cancer Research 263
- Periodontics 113
- Complementary and alternative medicine 108
Countries citing papers authored by Te‐Chun Hsia
This map shows the geographic impact of Te‐Chun Hsia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Te‐Chun Hsia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Te‐Chun Hsia more than expected).
Fields of papers citing papers by Te‐Chun Hsia
This network shows the impact of papers produced by Te‐Chun Hsia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Te‐Chun Hsia. The network helps show where Te‐Chun Hsia may publish in the future.
Co-authors
The 25 scholars most cited alongside Te‐Chun Hsia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 151 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1737 |
| 2 | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2020 | 522 |
| 3 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 498 |
| 4 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 493 |
| 5 | 2021 | 202 | |
| 6 | 2009 | 197 | |
| 7 | Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. | 1996 | 117 |
| 8 | Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study Hit paper breakdown → | 2023 | 113 |
| 9 | Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer Hit paper breakdown → | 2024 | 108 |
| 10 | 2011 | 106 | |
| 11 | 2021 | 106 | |
| 12 | 2019 | 101 | |
| 13 | 2003 | 60 | |
| 14 | Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. | 2002 | 56 |
| 15 | 2017 | 53 | |
| 16 | 2016 | 45 | |
| 17 | 2015 | 44 | |
| 18 | Interaction of methylenetetrahydrofolate reductase genotype and smoking habit in Taiwanese lung cancer patients. | 2010 | 37 |
| 19 | 2012 | 35 | |
| 20 | 2001 | 34 |
About Te‐Chun Hsia
Te‐Chun Hsia is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Genetics and Physiology, having authored 151 papers that have together received 5.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (31 papers), Genetic Associations and Epidemiology (16 papers), Asthma and respiratory diseases (15 papers), Protease and Inhibitor Mechanisms (12 papers), Lung Cancer Research Studies (11 papers), Lung Cancer Diagnosis and Treatment (10 papers), DNA Repair Mechanisms (8 papers) and Head and Neck Cancer Studies (7 papers). The work is most often cited by research in Oncology (2.6k citations), Pulmonary and Respiratory Medicine (1.7k citations), Cancer Research (263 citations), Periodontics (113 citations) and Complementary and alternative medicine (108 citations). Te‐Chun Hsia has collaborated with scholars based in Taiwan, China and United States. Frequent co-authors include Jing‐Gung Chung, Chih‐Yen Tu, Te‐Chun Shen, DA-TIAN BAU, Jai‐Sing Yang, Chia‐Hung Chen, WEN-SHIN CHANG, Wu‐Huei Hsu, Thomas P. Prindiville and Chia-Wen Tsai. Their work appears in journals such as Anticancer Research, Medicine, Environmental Toxicology, Journal of Thoracic Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.